Day One 15 April 2008 Tuesday
08.00 Registrations and refreshments
08.30 Organiser’s welcome remarks
08.45 Guest-of-honour address
Lim Hng Kiang, Minister
Ministry of Trade & Industry, Singapore
08.55 Chairman's welcome remarks
Murali K. Prahalad, Vice President, Molecular Biology Essentials
Invitrogen Corporation, USA
09.00 Global keynote address and executive interview: The evolving biomedical
science and industry
• Market trends and drivers of the biomedical industry and crystal balling future growth
• Emerging biomedical innovation from Asia and its impact
• The evolution of the global biotech capital market: Where and how does Asia fit into the
equation
Keynote speakers:
Gordon Binder, Managing Director, Coastview Capital, USA
Founder & former CEO, Amgen Inc, USA
Philippe Kourilsky, Chair of Immunology, College de France
Former Director General, Pasteur Institute, France
Ansbert Gadick, Founder & General Partner, MPM Capital, USA
Interviewer:
Lorraine Hahn, Journalist & TV Presenter, Former TV Talk-show-host & Anchor
CNN and CNBC, Hong Kong
10.00 Morning refreshments, BioMedical Technology Showcase session & combined 
THE BIOPHARMACEUTICAL MANUFACTURING IN ASIA-PACIFIC
11.00 Chairman’s opening remarks
Gerhard Klement, Chief Executive Officer & President of Biopharmaceuticals
Reliance Life Sciences, India
11.10 International Visionary Panel: Asia’s advantage: Achieving cost-effective
biologics production by setting up manufacturing base in Asia
• Advantages and challenges of setting up manufacturing base in Asia
• Discussing the major consideration factors in site selection
• How substantial is the cost benefit?
• Does the cost advantage outweigh the risk?
• What does the future hold for Asia’s biomanufacturing industry?
Moderator:
William Downey, President, HighTech Business Decisions, USA
Panelists:
Thibaud Stoll, Head of Global Biopharmaceutical Operations, Novartis, Switzerland
James Miller, Vice President & General Manager, Singapore Product Operations
Genentech, Singapore
Vincent Hingot, Project & Site Director, GSK Biologicals, Singapore
Michael Brown, Vice President of Operations & Site Manager, Lonza, Singapore
11.55 Asian Visionary Panel: Assessing the capability and capacity of Asia’s
biopharmaceutical manufacturing industry
• Status and current development of biomanufacturing industry in Asia
• Analyzing the regional biopharmaceutical market
• Assessing how well can Asia cope with the booming biomanufacturing industry in terms of
the talent pool, manufacturing technology and regulatory infrastructure
• Addressing key challenges- IP protection and GMP compliance
• Crystal balling the future of biomanufacturing in Asia
Moderator:
Jason Gale, Team Leader, Health and Science Asia, Bloomberg L. P., Singapore
Panelists:
Ya-Jun Guo, Director, Shanghai Cell Engineering & Antibody Centre, China
David Mashaal, Vice President of Global Business Development, SciGen, Singapore
Jun Yamaya, Vice President, CMC R&D Laboratories, Production Division
Kirin Pharma, Japan
Harish Iyer, General Manager of R&D, Biocon, India
12.40 Networking luncheon and showcase session
CELL CULTURE AND UPSTREAM PROCESSING
13.45 Keynote: Cell culture productivity improvements and challenges to downstream
processing efficiency
• The evolution of cell culture technologies in biologics manufacturing
• Reviewing the recent progresses and breakthroughs in cell culture productivity
• Addressing the impact on plant output and downstream process and how to overcome the
bottleneck
• Predicting how fast downstream processing can catch up given the ongoing improvements
in cell culture productivity for the next 10 years
Joseph Tarnowski, Senior Vice President, Biologics Manufacturing & Process
Development, Bristol-Myers Squibb, USA
14.15 Optimisation for glycoprotein production from mammalian cell culture
• Key drivers: maximise activity and minimise heterogeneity
• Design of cell and molecular biology
• Cell line selection & screening
• Design of the cell culture process
• Optimal protein recovery steps
George Lovrecz, Head of Fermentation,
CSIRO Molecular and Health Technologies, Australia
14.45 Case study: Process optimisation and scale up of a perfusion-based process for
monoclonal antibody production
• Manufacturing of epidermal growth factor receptor antibody, Nimotuzumab, utilising a
perfusion process based on spin filter technology
• Evaluating media and process parameters by simulating perfusion in shake flasks
• Scaling up of short listed conditions from 2L to 1000L perfusion bioreactors
• Extensive analysis of product from each scale for downstream purification and
characterisation
Harish Iyer, General Manager of R&D, Biocon, India
15.15 Afternoon refreshments, showcase session &
16.15 Application of HTP microfluidic culture systems to media and process
optimisation
• Current workflow limitations in developing media and bioreactor processes
• Scale-down models for validation in bioreactors
• New microfluidic technologies revealing synergies and predicting optimal conditions for
bioreactor performance
• Results of factorial or central composite experiments
• A cost effective way to validate media formulations and bioreactor parameters for scale-up
David Zhao, Technical Director for Media Development, Invitrogen, USA
PAT AND QUALITY BY DESIGN
16.45 PAT architecture for process development and biomanufacturing- building the
business case for PAT
• Integrating PAT with the existing infrastructure
• Designing a PAT infrastructure for process development and for manufacturing, including
examples of PAT architecture
• PAT project development- step-by-step PAT infrastructure implementation and developing
the future control and release philosophy
• PAT as a continuous process understanding improvement tool and the role of Knowledge
Management Systems
Ingrid Maes, Senior Consultant Innovative Technologies, Siemens, Belgium
17.15 Chairman’s closing remarks
Gerhard Klement, Chief Executive Officer & President of Biopharmaceuticals
Reliance Life Sciences, India
17.30 Close of day one
19.00 BioMedical Industry Awards Dinner
Day Two 16 April 2008 Wednesday
08.00 Registration and refreshments
08.45 Chairman’s opening remarks
James Miller, Vice President & General Manager, Singapore Product Operations
Genentech, Singapore
DOWNSTREAM PROCESSING
09.00 The presence and future of large scale biochromatography
• Initial recovery: Keeping the pace with fermentation
• Capturing: Is chromatography a lame duck?
• Polishing: Disposable concepts are en vogue
• Virus safety: New guidelines provide chances, not threats
• Process economy: Ways out of the fixed-cost trap
Uwe Gottschalk, Group Vice President, Purification Technologies
Sartorius Stedium Biotech, Germany
09.30 A cost-reducing approach by bridging the gap between upstream productivity
and downstream processing efficiency
• Tackling the backlog in bioseparation
• New purification protocols to greatly reduce cost and batch processing time
• Exploring cost-saving non-Protein A purification processes- comparison of effects with
traditional Protein A purification
• Increasing productivity by integration, reduced cycle times and built-in automation
Alahari Arunakumari, Senior Director, Medarex, USA
10.00 Case study: Increasing downstream processing capacity for high-titer antibody
production
• Innovations in downstream processing to accommodate improvements in antibody
expression titers and throughput
• Strategies to increase downstream capacity without compromising economics and purity of
antibodies
• Future challenges in downstream processing
Dan Slone, Senior Director, Manufacturing Purification, Celltrion, Korea
10.30 Morning refreshments and showcase session
PRODUCTIVITY AND ECONOMY IN BIOPROCESSES
11.00 Manufacturing planning in biopharmaceutical operations
• Build, retrofit or outsource- committing assets well in advance of sales
• Lowering COGS by process improvements
• Patents impacting manufacturing planning
• Commercial scale planning
• Single- versus multi-product facility
Gerhard Klement, Chief Executive Officer & President of Biopharmaceuticals
Reliance Life Sciences, India
11.30 Integrated process design throughout the product life cycle
• Developing platform technologies to support a diverse portfolio of products
• Integrating and harmonising upstream and downstream processes
• Implementing appropriate control strategies based on process and product understanding
• Discussing integrated process designs to generate effective regulatory strategies
David Glover, Director of Bioprocess R&D, UCB Celltech, UK
12.00 Networking luncheon and showcase session
DISPOSABLE TECHNOLOGY
13.15 Economics of adopting single-use bioprocess containers in Asian manufacturing
scenario
• The actual cost of adopting disposable bioprocess containers (BPC)- set up including bags,
accessories, connections, mixing devices
• Costing of high quality fixed volume, multiuse stainless steel tanks fabricated in Asia
• Overall cost of ownership of steel tanks versus single-use bioprocess containers including
capital cost, validations and maintenance
• Preferred scenarios with advantages of one technology over other
• Investigating if the US or European basis of choosing one technology over other is
applicable to Asian manufacturers or not
Swapnil Ballal, Head of Biopharmaceutical Bulk Manufacturing
Intas Biopharmaceuticals, India
13.45 Discussion panel: Advantages and limitations of using disposables in
biopharmaceutical manufacturing
• Pros and cons of using disposable systems in upstream and downstream processing
• What can be single-use and what cannot
• Assessing the potential for single-use affinity chromatography columns
• Disposal challenges of large single-use equipments
• Addressing regulatory and validation concerns
Moderator:
Swapnil Ballal, Head of Biopharmaceutical Bulk Manufacturing
Intas Biopharmaceuticals, India
Panelists:
Dan Slone, Senior Director, Manufacturing Purification, Celltrion, Korea
Alahari Arunakumari, Senior Director, Medarex, USA
Günter Jagschies, Director Customer Applications R&D,
GE Healthcare LifeSciences, Sweden
OPERATIONAL EXCELLENCE- LEAN MANUFACTURING
14.30 Leveraging Manufacturing Automation & Information Solutions to Achieve
Operational Excellence
• Review of Industry challenges driving the need to focus on manufacturing for stategic
advantage
• Operational Excellence and Enterprise Automation & Information Solutions
• Focus Solutions and case studies
• Results of executing an operational excellence strategy
Anthony V. Sollazo, Industry Solutions Manager - Life Sciences Asia Pacific,
Rockwell Automation, Hong Kong
15.00 Achieving operational excellence through lean manufacturing
• Overview of lean manufacturing- waste reduction in terms of time, labour and materials,
paradigm changes in pharmaceutical product lifetimes and applying lean principles in
biopharmaceutical manufacturing
• Lean concepts in process design and manufacturing implementation and quality systems
• Maximizing manufacturing efficiency by implementing lean concepts right from the start
• Challenges in lean manufacturing implementation
• Meeting FDA regulatory requirements in a lean manufacturing environment
Donald F. Gerson, Chief Operating Officer & President, Celltrion, Korea
15.30 Implementing lean in biopharmaceutical manufacturing – learning from the
automotive industry
• Incentives to implement lean in (bio)pharmaceutical manufacturing, taking into account
increasing challenges on time, COGS and compliance
• Examples where lean principles have been applied successfully to large-scale
biopharmaceutical manufacturing, leading to improvements in throughput rate, throughput
time, productivity, capacity and “waste” reduction
• Recommendations on additional potential of Lean implementation to gain some significant
competitive edge
Thibaud Stoll, Head of Global Biopharmaceutical Operations, Novartis, Switzerland
16.00 Afternoon Refreshment and showcase session
16.30 Interactive round table discussion
This round table discussion session is an open moderated session where delegates can
choose to join a small focus group to discuss a pre-selected topic of their interest.
Moderated by key industry experts, the round table discussion will ensure debate and
discussion on thought-provoking and controversial issues with industry peers.
Focus Group 1: Building a world-class GMP-compliant manufacturing facility in
Asia
• What are the consideration factors and planning to be done before committing?
• How do you manage the risks involved? How to design the most appropriate facility
according to your needs?
Focus Group 2: Future technologies in biologics manufacturing
• What are the current limitations in biomanufacturing technologies?
• What kind of technological improvements will be needed to meet the growing demand of
the biopharmaceutical manufacturing industry for the next 10 years?
17.15 Chairman’s closing remarks
James Miller, Vice President & General Manager, Singapore Product Operations
Genentech, USA
17.25 Close of conference
Contract Manufacturing Summit
Monday 14 April 2008
Sponsored by 
08.45 Chairman’s opening remarks
Bruce Register, Chief Executive Officer & President
Trusgen, USA
OUTSOURCING BIOPHARMACEUTICAL MANUFACTURING TO ASIA
09.00 Opening address: Beyond Asia: Taking the Asian biopharmaceutical revolution to
the world stage
• Biopharmaceutical innovation across Asia represents an unprecedented explosion of novel
approaches to curing and treating debilitating diseases.
• The most successful Asian companies will need to move beyond the Asian marketplace
• Cooperation with "Western" manufacturing service providers have the potential to catapult
local Asian products and technologies
• Partnerships will give Asian companies access to world-class expertise and a track record
Stefan Borgas, Chief Executive Officer
Lonza, Switzerland
9.30 Keynote: Current trends and developments in the global biopharmaceutical
contract manufacturing
• Global presence of CMO emerge to facilitate time-to-clinic approach
• Maximising capacity utilisation to achieve enhanced productivity in contract manufacturing
• Strategies in determining product quality and increasing overall yield and process economy
• Achieving competitive advantage and worldwide regulatory compliance in contract
manufacturing
Rolf Werner, Corporate Senior Vice President, Biopharmaceuticals
Boehringer Ingelheim, Germany
10.00 Discussion Panel: Should you outsource to Asia?
• Discussing the advantages in engaging Asian CMOs, such as pricing and gain of access to
Asian markets
• Challenges- IP protection, GMP compliance, technology transfer and distance
• What is the future for Asia’s biomanufacturing industry?
Moderator:
Scott M. Wheelwright, President & Chief Executive Officer
Strategic Manufacturing Worldwide, USA
Panelists:
Joseph Tarnowski, Senior Vice President, Biologics Manufacturing & Process Development
Bristol-Myers Squibb, USA
Hajimu Sakamoto, Vice President, Business Development
Artisan Pharma, USA
Joseph Santangelo, Development Director
SingVax, Singapore
Kochung Lin, Chief Executive Officer
PharmaEssential Corp., Taiwan
10.45 Morning refreshments
11.15 Strategies in ensuring successful technology transfer across continents
• Analysing the challenge of changing production environments
• Overcoming the hurdle of crossing cultural boundaries
• Sharing tried and tested methods for successful technology transfer
• Discussing case study examples
Scott M. Wheelwright, President & CEO
Strategic Manufacturing Worldwide, USA
PARTNERING WITH ASIA CMO
11.45 Opening the door to Asian CMOs: Taking down the barriers
• What are the barriers that keep Asian CMOs from the small to medium biotech market?
• How can CMO's best communicate their value?
• How long will the window of opportunity be open to Asian CMOs?
Bruce Register , CEO & President,
Trusgen, USA
12.15 Networking luncheon
13.30 Case study: Successful transfer from Bristol-Myers Squibb to Celltrion
• Asian contract manufacturing business and operational advantages
• Technology transfer and scale-up issues
• Contractual and operational relationships
• Quality system harmonization
• Regulatory harmonization and licensure (KFDA and US FDA)
• Ongoing strategies for supply chain maintenance
Donald F. Gerson, Chief Operating Officer & President
Celltrion, Korea
ASIA-PACIFIC CMO PARADE
Home-grown CMOs in Asia are invited to share their views of the region’s contract biologics manufacturing industry and give case-study presentations to exemplify their capacities and technologies in handling contracted biomanufacturing projects.
14.00 Presentation by Inno Biologics
Dato' Dr Nazlee Mohd Kamal, Chief Executive Officer
Inno Biologics, Malaysia
14.15 Presentation by Intas Biopharmaceuticals
Swapnil Ballal, Head of Biopharmaceutical Bulk Manufacturing
Intas Biopharmaceuticals, India
14.30 Presentation by Asahi Glass
Hiroko Tsukamoto, Marketing Director
Asahi Glass, Japan
14.45 Presentation by Reliance Life Sciences
Jay Madan, Vice President of Business Development
Reliance Life Sciences, India
15.00 Afternoon refreshments
15.45 Interactive Round Table Discussion
This round table discussion session is an open moderated session where delegates can
choose to join a small focus group to discuss a pre-selected topic of their interest.
Moderated by key industry experts, the round table discussion will ensure debate and
discussion on thought-provoking and controversial issues with industry peers.
Focus Group 1:
Opportunities for Asia Pacific CMOs in emerging therapeutics- vaccines and stem
cells
How can CMOs capitalise on the growing vaccine and stem cells industry in Asia Pacific?
What are the unique specifications required? What are the challenges and how to overcome
the hurdles?
Donald F. Gerson, Chief Operating Officer & President
Celltrion, Korea
Focus Group 2:
Best strategies in streamlining an efficient technology transfer process for
outsourced biopharmaceutical manufacturing
How do you ensure smooth and effective technology transfer to CMO in the shortest possible
time especially when clients have not manufactured at full scale? How to achieve strong
communication between client and CMO?
Scott M. Wheelwright, President & Chief Executive Officer
Strategic Manufacturing Worldwide, USA
16.45 Chairman’s closing remarks
Bruce Register, Chief Executive Officer & President
Trusgen, USA
17.00 Close of pre-conference day
17.30 Site visit to Biopolis
Clinical Partnering Summit
Thursday 17 April 2008
Sponsored by 
08.45 Chairman’s opening remarks
Raymond Chua, Managing Director & Regional Medical Director (Asia Pacific, Oceania &
Middle East), Eisai Clinical Research, Singapore
CURRENT TRENDS & DEVELOPMENT OF THE CLINICAL TRIAL INDUSTRY IN ASIA PACIFIC
09.00 Opening Keynote: Country and site selection for global clinical trials:
Opportunities and challenges
• R&D drivers for clinical development entry into new theatres of operations
• Benefits of doing global clinical studies in emerging countries, namely India, China/Asia
and Latin America, and the guiding principles
• Country selection- country assessment criteria, sources of information for assessment,
country-by-country analysis
• Site selection- what do sponsors look for? How do investigators find sponsors? What can
investigator sites do to improve their chances for selection for clinical trials? What are
some of the investigator site best practices that we have seen?
• Amgen’s conclusions and recommendations
Fidela Moreno, Executive Director, Global Development Operations
Asia and Latin America, Amgen, USA
09.30 Developing clinical trials in new emerging countries in Asia
• Rationale for developing clinical trials in emerging Asian countries- Indonesia, Vietnam,
Pakistan, Bangladesh and Sri Lanka
• Diligence prior to commencing activities
• Common challenges
• Case studies
Anand Tharmaratnam, Head of Clinical Development, Asia Pacific & Chief Executive
Officer, South East Asia, Quintiles East Asia, Singapore
10.00 Morning refreshments
CONDUCTING CLINCIAL TRIALS IN ASIA PACIFIC
10.30 Joint Discussion: Navigating the regulations in China, India and Australia
Clinical experts from the various emerging markets- China, India and Australia- would each
give a 15 min presentation on the clinical trial regulatory framework in the respective
country, and followed by a 10 min Q&A session that is open to the audience.
Moderator:
Christophe Tournerie, Executive Director, Clinical Research-AsiaMedical,
PharmaNet, Singapore
Panelists:
George Chen, Area Medical Vice President & Chief Medical Officer
GSK, China/Hong Kong
S. K. Gupta, Director General & Dean
Institute of Clinical Research India, India
James Garner, Vice President of Clinical & Medical Affairs
Progen Pharmaceuticals, Australia
11.15 Meeting challenges in clinical research in Asia Pacific
• Understanding regulatory specificities and how to overcome potential issues
• Saturation of existing sites and scarcity of clinical research professionals in the region
• Competitive cost vs US and Europe
• Fast patient recruitment and compliance with ICH GCPs
• Adapting start-up strategies to each country specificities
Christophe Tournerie, Executive Director, Clinical Research-Asia
PharmaNet, Singapore
11.45 Case study: Effectively conducting clinical trials in China
• Sharing experience in conducting clinical trials in China
• Site selection, investigator training and qualification and patient recruitment issues
• Assessing current clinical trial infrastructure in hospitals in China and how to maximize
clinical trial quality and efficiency given the present infrastructure
George Chen, Area Medical Vice President & Chief Medical Officer
GSK, China/Hong Kong
12.15 Networking luncheon
13.30 Managing talent in the highly demand driven clinical trial industry in Asia
• Discussing recruitment strategies to address the shortage of clinical research talent in Asia
• Retention, training and development- understanding the needs of your staff
• Managing clinical staff at the global, regional and country level
• Planning ahead for your staffing needs
Ross Horsburgh, Vice President, Global Clinical Development
Kendle, Singapore
14.00 Panel Discussion: Effective ways to reach out to your desired patient pools in
Asia
• Strategies for gaining fast and cost-effective access to targeted patient groups in Asia’s
huge patient population
• Sharing of effective patient recruitment campaigns across Asia
• Discussing unique issues, such as ethical consideration and obtaining informed consent,
faced in patient recruitment and retention in different cultures
• Recruitment of patients with very unique disease profile or specific treatment window
Moderator:
Fidela Moreno, Executive Director, Global Development Operations, Asia and Latin
America, Amgen, USA
Panelists:
Rose Qiu, Head of Global Clinical Operation, Asia Pacific
Johnson & Johnson, China
James Garner, Vice President of Clinical & Medical Affairs
Progen Pharmaceuticals, Australia
Ross Horsburgh, Vice President, Global Clinical Development,
Kendle, Singapore
SUCCESSFUL CLINICAL PARTNERSHIPS IN ASIA-PACIFIC
14.45 Strategies for a successful clinical partnership between sponsors and CROs
• Consideration factors in selecting the right CRO for your clinical trials
• Sharing clinical partnership experience from a sponsor’s perspective
• Best practices in establishing collaboration with CROs in conducting clinical study to
maximise team performance and minimise study time
• Building a strong long-term working relationship with CRO
Raymond Chua, Managing Director & Regional Medical Director (Asia Pacific, Oceania &
Middle East), Eisai Clinical Research, Singapore
15.15 Afternoon refreshments
15.45 Panel Discussion: Strategies for small pharma/biotech in partnering with a large
CRO
• Assessing the needs of small pharma/biotech companies in performing clinical research
and how their needs differ from large pharma
• Discussing the different outsource models that CRO can employ in partnering with small
pharma/biotech and how best to cater to them
• Analysing steps that can be taken by both sides to ensure the most effective execution of
clinical project
Moderator:
Paul Anderson, Managing Director
Orthocell Pty Ltd, Australia
Panelists:
Kochung Lin, CEO
PharmaEssentia Corp., Taiwan
Satish Totey, CSO
Stempeutics, India
Narinder Chopra, Director, Clinical Operations
CombinatoRx, Singapore
Anand Tharmaratnam, Head of Clinical Development, Asia Pacific & Chief Executive
Officer, South East Asia, Quintiles East Asia, Singapore
16.30 Interactive roundtable discussion
This round table discussion session is an open moderated session where delegates can
participate in a small focus group to discuss a pre-selected topic in an informal setting.
Moderated by key industry expert, the round table discussion will ensure debate and
discussion on thought-provoking and controversial issues with industry peers.
Selecting the right CRO for your clinical research activities in Asia
When should you outsource your clinical activities? How can you outsource in the most cost-
effective and productive manner? What are the consideration factors in choosing a CRO
partner?
James Garner, Vice President of Clinical & Medical Affairs
Progen Pharmaceutical, Australia
17.15 Chairman’s closing remarks
Raymond Chua, Managing Director & Regional Medical Director (Asia Pacific, Oceania &
Middle East), Eisai Clinical Research, Singapore
17.30 Close of post conference day
Post Conference Masterclass
Thursday 17 April 2008
* Registration for the Masterclass will commence at 08.30am. The class will commence from 9am
to 5pm and refreshments & lunch will be served at appropriate times.
Virus and prion clearance of biopharmaceuticals
With the current regulatory requirements ensuring viral safety of biotechnological products, orthogonal strategies for virus clearance must be implemented early-on in the manufacturing process. At least two complementary methods should be utilised in order to meet the specifications set forth by the regulatory organisations.
This will stress the need for implementation of robust and efficient technologies in order to meet the requirements of “risk assessmentbased” virus clearance approaches. Such technologies ideally involve virus removal by nanofiltration, inactivation by UVC and adsorption by membrane chromatography. Additionally, the platform must be characterized by high virus LRVs and product recovery, independent of their position in the downstream process as well as the use of disposable technologies in order to meet the flexibility needed in earlystage process development.
This masterclass will address the following issues:
• Current regulatory expectations on viral safety for biopharmaceuticals early-on in production
• Need for a risk based pragmatic approach to viral safety assurance
• Orthogonal Virus Clearance Technologies – Inactivation, absorption and removal
• Disposables in viral clearance
• Design of virus clearance evaluation (validation) studies in the laboratory
• Case studies
Benefits of attending
• Be informed of the basics required to plan an adequate viral safety program
• Recognise the necessity for incorporating multifaceted and complementary virus control strategies
• Realise how much clearance needs to be incorporated into the manufacturing process in order to
ensure viral safety of the product
• Develop an insight into how to evaluate the available viral clearance strategies
Who should attend?
• Viral safety scientists
• Research scientists
• Bioprocess, manufacturing and production scientists
• Quality assurance and control professionals
Masterclass leader: Suma Ray, Process Development Scientist
Sartorius-Stedim Biotech, India
Back to top
|
